Levothyroxine is taken daily by tens of millions of Americans who assume, quite reasonably, that the right dose makes all the difference. The drug replaces the hormone that a faltering thyroid can no longer make in adequate amounts. Swallow it every morning, get your blood tested every few months, and adjust if needed. That’s the plan. What makes a large body of emerging research uncomfortable is a finding that cuts against that reassuring routine: for a meaningful share of patients on thyroid hormone therapy, the dose they’re on may itself be raising their risk of dying from heart disease, regardless of which direction the dosing error runs.
The condition the drug treats, hypothyroidism, is more common than many people realize. Hypothyroidism affects up to 20 million people in the United States, and one synthetic thyroid hormone, levothyroxine, has landed on the United States list of top three prescribed medications in the country over the last decade. Given that heart disease remains the leading cause of death in Americans, affecting nearly half of the population aged 20 years and older, the intersection of these two realities carries considerable weight. Getting the dose wrong, in either direction, appears to carry consequences that go well beyond symptom management.
The core problem isn’t that the medication is dangerous in itself. Dosing it precisely is harder than it looks, and far more people are outside the therapeutic window than most patients are ever told. Thyroid hormone regulation runs through a feedback loop, and the marker doctors rely on to measure it, thyroid-stimulating hormone (TSH), must land in a specific range for the treatment to be genuinely protective. When it drifts too high or too low, the heart pays a price.
What the Research Really Reveals About the Link Between Thyroid Medication and Heart Health Risks
The most substantial piece of evidence on this comes from a 2022 retrospective cohort study published in JAMA Network Open, led by Dr. Maria Papaleontiou, M.D., an endocrinologist and Associate Professor at the University of Michigan’s Division of Metabolism, Endocrinology and Diabetes. Papaleontiou examined the relationship between thyroid hormone treatment intensity and cardiovascular mortality in a cohort of more than 705,000 U.S. veterans who received thyroid hormone therapy between 2004 and 2017. The numbers from that study are hard to minimize: after adjusting for age, sex, race, ethnicity, and traditional cardiovascular risk factors including hypertension, smoking, and previous heart disease, patients with TSH levels outside the normal range had an increased risk for cardiovascular mortality compared to those with normal thyroid function.
Up to half of patients who receive thyroid hormone therapy have TSH levels inappropriately below or above the normal range. The consequences of that mismanagement aren’t abstract: in Papaleontiou’s cohort, both overtreatment and undertreatment were independently linked to a higher risk of dying from a cardiovascular cause. In practical terms, that means a patient whose dose is slightly too high and another whose dose is slightly too low are both facing elevated cardiac risk compared to a patient whose levels are well-controlled.
People taking thyroid hormone are at risk for subclinical hyperthyroidism, whether intentional or unintentional, and this can increase the risk for cardiovascular disease and death. The extremes carry the most danger. The risk is greatest when TSH is very low (below 0.1) or very high (above 20), but research suggests patients don’t need to be at those extremes to face elevated cardiovascular risk. Any consistent deviation from the normal range appears to matter.
The Overtreatment Problem and Its Cardiac Consequences
One specific pattern deserves attention: the silent overtreatment that happens when doctors maintain patients on doses high enough to push TSH below normal range without symptoms flagging the problem. Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, creating a state that mimics mild hyperthyroidism – a thyroid that’s working too hard. The body can’t easily distinguish between its own excess thyroid hormone and an overdose from a pill.
What does that do to the heart? A persistently low TSH can lead to an increased risk for atrial fibrillation, an irregular heartbeat that raises the risk of stroke and heart failure. Excess thyroid hormone is a well-documented risk factor for the development of atrial fibrillation. A 2025 study published in Military Medicine found that in hypothyroid patients treated with levothyroxine, higher circulating levels of free thyroxine (fT4) are associated with increased risk of incident atrial fibrillation, strengthening the case that even normal-looking TSH doesn’t guarantee cardiac safety if the actual hormone level is running high.
For patients with thyroid cancer, the overtreatment risk is more deliberate but no less concerning. TSH suppression therapy, where doses are intentionally set high to keep TSH below normal and prevent cancer recurrence, increases the risk of atrial fibrillation compared to controls. Balancing cancer management against cardiovascular harm is one of the genuinely difficult clinical trade-offs in endocrinology.
Undertreatment Carries Its Own Cardiovascular Risk
The flip side of the problem is undertreatment, and it’s every bit as consequential. When TSH remains persistently elevated because the dose isn’t sufficient, the body stays in a state of relative hypothyroidism, which carries its own cluster of cardiac risks.
Thyroid hormones act on the heart through various mechanisms, and subclinical hypothyroidism has been associated with risk factors for cardiovascular disease, such as hypertension and dyslipidemia. A 2019 review published in the journal Frontiers in Endocrinology found that overt hypothyroidism is associated with an increased risk for atherosclerotic cardiovascular disease due to the metabolic and hemodynamic changes that occur when thyroid hormone levels are chronically low. A persistently elevated TSH can lead to increased cholesterol levels, which in turn raises the risk of heart disease.
A 2017 meta-analysis published in BMC Medicine, drawing on 55 cohort studies involving nearly 1.9 million participants, confirmed that patients with hypothyroidism experienced higher risks of ischemic heart disease (reduced blood flow to the heart, the condition that causes heart attacks), myocardial infarction, and cardiac mortality compared to people with normal thyroid function. An undertreated thyroid condition doesn’t just make a person feel tired and sluggish; it actively accelerates the processes that damage the cardiovascular system over time.
The Heart Failure Question
Perhaps the most clinically sensitive finding in recent research involves patients who already have heart failure. For this group, the risk calculations around levothyroxine become particularly complex. A 2025 study published in Thyroid Research Journal found that levothyroxine treatment in patients with heart failure may result in an increased risk of death and adverse events, though the results are limited by the lack of complete clinical information.
In a more specific subset, research published in JACC: Heart Failure found that in heart failure patients with preserved ejection fraction (meaning the heart’s pumping function appears normal on tests) and normal TSH, levothyroxine supplementation was associated with a 9% increased risk of acute heart failure. The finding is counterintuitive: patients who appear to have normal thyroid levels still experienced harm from supplementation. This suggests the relationship between levothyroxine and cardiac risk isn’t simply about correcting a deficiency, but about the precise biological effects of the drug itself on an already stressed heart.
Who Is Most at Risk and What the Guidelines Say
According to the American Thyroid Association, women are five to eight times more likely than men to have thyroid problems, making the female proportion of the levothyroxine-using population substantial. Most of those people are managing a condition rooted in autoimmunity. Autoimmune thyroiditis accounts for 90 to 95% of overt hypothyroidism cases in developed countries.
Older adults face a particular challenge. A 2025 review published in Frontiers in Endocrinology found that levothyroxine provided no apparent benefits in terms of cardiovascular events or cardiovascular mortality in older persons with subclinical hypothyroidism. Subclinical hypothyroidism is the milder form of the condition, where TSH is elevated but the thyroid hormone itself is still in the normal range, and symptoms may be minimal or absent. Treating it aggressively in older patients appears to offer limited cardiovascular return and may introduce cardiac harm.
A 2020 review published in Frontiers in Endocrinology by researchers at UCLA David Geffen School of Medicine concluded that the use of levothyroxine in subclinical hypothyroidism to reduce cardiovascular disease risk is not clearly beneficial, with treatment possibly providing benefit only in certain subgroups, such as younger patients or those at higher cardiovascular risk. Most international societal guidelines advise that treatment decisions should be individualized based on patient age, degree of TSH elevation, symptoms, cardiovascular disease risk, and other comorbidities.
That individualization is key. The appropriate question is whether a specific patient’s current dose is keeping their TSH consistently within a normal range, and whether their heart health is being factored into that target.
Read More: Signs, Symptoms and Treatments of Thyroid Disorders
What This Means for You
The central takeaway from this body of research is a reframing of what “well-managed” thyroid treatment actually looks like. Staying on the medication isn’t enough. The goal of treating hypothyroidism is achieving a TSH in the normal range, and not over- or undertreating the condition is critically important. Anyone on levothyroxine should know their most recent TSH number, not just that it was “fine,” and should be asking their doctor whether their levels have been consistently in range over successive tests, not just at one time point.
For patients with pre-existing heart disease, the stakes are higher. The evidence suggests that both the direction and the degree of TSH deviation matter, and that the cardiovascular risks compound when thyroid levels sit outside the target zone for extended periods. Patients managing both hypothyroidism and a heart condition should be discussing their TSH target explicitly with their cardiologist and their endocrinologist or primary care provider, since the optimal TSH range for cardiac protection may differ from the conventional reference range used for healthy adults.
The Bottom Line
Patients over 65 and those with existing heart failure should be especially attentive. The research on older adults with subclinical hypothyroidism suggests that routine treatment may not be warranted from a cardiac standpoint, and that a watchful monitoring approach may be as appropriate as prescribing. If you’re in this group and your doctor is recommending levothyroxine based on a mildly elevated TSH alone, asking what the expected cardiovascular benefit is, and whether the evidence in older patients supports that reasoning, is a fair and informed question to bring to the next appointment.
Three practical steps follow from all of this. First, get your actual TSH number at every test – “it’s normal” is not a number. Second, if you’ve been on the same levothyroxine dose for more than a year without a TSH recheck, ask for one. Third, if you have any form of heart disease or are over 65 with only mildly elevated TSH, ask your doctor directly whether the cardiovascular evidence supports treatment in someone with your profile. These aren’t adversarial questions – they’re the kind a well-informed patient asks, and any physician confident in their reasoning should welcome them.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: 10 Foods to Help Support Thyroid Health